Splice modification to restore functional dystrophin synthesis in duchenne muscular dystrophy

Current Pharmaceutical Design

Volumn 16, Issue 8, 2010, Pages 988-1001

  Wilton, Steve D ^a   Fletcher, Susan ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antisense oligomer; Becker muscular dystrophy; Duchenne muscular dystrophy; Dystrophin; Exon skipping; Molecular medicine

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; OLIGOMER;

ALTERNATIVE RNA SPLICING; BECKER MUSCULAR DYSTROPHY; DUCHENNE MUSCULAR DYSTROPHY; EXON; EXON SKIPPING; GENE EXPRESSION; GENE MUTATION; HUMAN; MEDICAL ETHICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; RNA SPLICING; STEM CELL; VIRAL GENE THERAPY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DYSTROPHIN; EXONS; GENE DELETION; GENE THERAPY; HUMANS; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; STEM CELL TRANSPLANTATION;

EID: 77950192254     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790883480     Document Type: Review

References (117)

1. Gerstein MB, Bruce C, Rozowsky JS, Zheng D, Du J, Korbel JO, et al. What is a gene, post-encode? History and updated definition. Genome Res 2007; 17: 669-681
2. Beadle GW, Tatum EL. Genetic control of biochemical reactions in neurospora. Proc Natl Acad Sci USA 1941; 27: 499-506.
3. Avery OT, MacLeod CM, McCarthy M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. J Exp Med 1944; 79: 137-158
4. Avery OT, MacLeod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type iii. 1944. Mol Med 1995; 1: 344-365
5. Crick FH. On protein synthesis. Symp Soc Exp Biol 1958; 12: 138-163
6. Berget SM, Moore C, Sharp PA. Spliced segments at the 5′ terminus of adenovirus 2 late mRNA. Proc Natl Acad Sci USA 1977; 74: 3171-3175
7. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-458
8. Emery AE. The muscular dystrophies. Lancet 2002; 359: 687-695
9. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002; 12: 926-929
10. den Dunnen JT, Bakker E, van Ommen GJ, Pearson PL. The DMD gene analysed by field inversion gel electrophoresis. Br Med Bull 1989; 45: 644-658
11. Love DR, Byth BC, Tinsley JM, Blake DJ, Davies KE. Dystrophin and dystrophin-related proteins: A review of protein and rna studies. Neuromuscul Disord 1993; 3: 5-21.
12. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988; 2: 90-95
13. Prior TW, Bartolo C, Pearl DK, Papp AC, Snyder PJ, Sedra MS, et al. Spectrum of small mutations in the dystrophin coding region. Am J Hum Genet 1995; 57: 22-33.
14. Prior TW, Bridgeman SJ. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. J Mol Diagn 2005; 7: 317-326
15. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP, et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the "Power" of therapeutic trials based on the natural history. Muscle Nerve 1983; 6: 91-103.
16. Nicholson LV. The "Rescue" of dystrophin synthesis in boys with Duchenne muscular dystrophy. Neuromuscul Disord 1993; 3: 525-531
17. Fanin M, Hoffman EP, Saad FA, Martinuzzi A, Danieli GA, Angelini C. Dystrophin-positive myotubes in innervated muscle cultures from Duchenne and Becker muscular dystrophy patients. Neuromuscul Disord 1993; 3: 119-127
18. Hoffman EP, Morgan JE, Watkins SC, Partridge TA. Somatic reversion/suppression of the mouse mdx phenotype in vivo. J Neurol Sci 1990; 99: 9-25.
19. Sherratt TG, Vulliamy T, Dubowitz V, Sewry CA, Strong PN. Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am J Hum Genet 1993; 53: 1007-1015
20. Wallgren-Pettersson C, Jasani B, Rosser LG, Lazarou LP, Nicholson LV, Clarke A. Immunohistological evidence for second or somatic mutations as the underlying cause of dystrophin expression by isolated fibres in xp21 muscular dystrophy of Duchenne-type severity. J Neurol Sci 1993; 118: 56-63.
21. Lu QL, Morris GE, Wilton SD, Ly T, Artem'yeva OV, Strong P, et al. Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol 2000; 148: 985-996
22. Wilton SD, Dye DE, Blechynden LM, Laing NG. Revertant fibres: A possible genetic therapy for Duchenne muscular dystrophy? Neuromuscul Disord 1997; 7: 329-335
23. Wilton SD, Dye DE, Laing NG. Dystrophin gene transcripts skipping the mdx mutation. Muscle Nerve 1997; 20: 728-734
24. Schatzberg SJ, Anderson LV, Wilton SD, Kornegay JN, Mann CJ, Solomon GG, et al. Alternative dystrophin gene transcripts in golden retriever muscular dystrophy. Muscle Nerve 1998; 21: 991-998
25. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion. Am J Hum Genet 1989; 45: 498-506.
26. Ginjaar IB, Kneppers AL, v d Meulen JD, Anderson LV, Bremmer-Bout M, van Deutekom JC, et al. Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family. Eur J Hum Genet 2000; 8: 793-796
27. Gualandi F, Trabanelli C, Rimessi P, Calzolari E, Toffolatti L, Patarnello T, et al. Multiple exon skipping and RNA circularisation contribute to the severe phenotypic expression of exon 5 dystrophin deletion. J Med Genet 2003; 40: e100.
28. Feng J, Yan JY, Buzin CH, Sommer SS, Towbin JA. Comprehensive mutation scanning of the dystrophin gene in patients with nonsyndromic X-linked dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 1120-1124
29. Hegde MR, Chin EL, Mulle JG, Okou DT, Warren ST, Zwick ME. Microarray-based mutation detection in the dystrophin gene. Hum Mutat 2008; 29: 1091-1099
30. Disset A, Bourgeois CF, Benmalek N, Claustres M, Stevenin J, Tuffery-Giraud S. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. Hum Mol Genet 2006; 15: 999-1013.
31. Nishiyama A, Takeshima Y, Zhang Z, Habara Y, Tran TH, Yagi M, et al. Dystrophin nonsense mutations can generate alternative rescue transcripts in lymphocytes. Ann Hum Genet 2008; 72: 717-724
32. Fernandez-Cadenas I, Andreu AL, Gamez J, Gonzalo R, Martin MA, Rubio JC, et al. Splicing mosaic of the myophosphorylase gene due to a silent mutation in Mcardle disease. Neurology 2003; 61: 1432-1434
33. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34: 135-144
34. Fanin M, Freda MP, Vitiello L, Danieli GA, Pegoraro E, Angelini C. Duchenne phenotype with in-frame deletion removing major portion of dystrophin rod: Threshold effect for deletion size? Muscle Nerve 1996; 19: 1154-1160
35. Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 1993; 90: 8673-8677
36. Takeshima Y, Nishio H, Sakamoto H, Nakamura H, Matsuo M. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin kobe. J Clin Invest 1995; 95: 515-520
37. Aartsma-Rus A, van Ommen GJ. Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA 2007; 13: 1609-1624
38. Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S, et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 1999; 9: 330-338
39. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001; 98: 42-47
40. Mann CJ, Honeyman K, McClorey G, Fletcher S, Wilton SD. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 2002; 4: 644-654
41. Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 2007; 15: 1288-1296
42. Errington SJ, Mann CJ, Fletcher S, Wilton SD. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. J Gene Med 2003; 5: 518-527
43. Harding PL, Fall AM, Honeyman K, Fletcher S, Wilton SD. The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther 2006; 15: 157-166
44. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 2006; 13: 1373-1381
45. Adams AM, Harding PL, Iversen PL, Coleman C, Fletcher S, Wilton SD. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: Cocktails and chemistries. BMC Mol Biol 2007; 8: 57.
46. Mitrpant C, Fletcher S, Iversen PL, Wilton SD. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping. J Gene Med 2009; 11: 46-56.
47. Aartsma-Rus A, De Winter CL, Janson AA, Kaman WE, Van Ommen GJ, Den Dunnen JT, et al. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: Indication for steric hindrance of SR protein binding sites. Oligonucleotides 2005; 15: 284-297
48. Aartsma-Rus A, van Vliet L, Hirschi M, Janson AA, Heemskerk H, de Winter CL, et al. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 2009; 17: 548-553
49. Schellenberg MJ, Ritchie DB, MacMillan AM. Pre-mRNA splicing: A complex picture in higher definition. Trends Biochem Sci 2008; 33: 243-246
50. Wilton SD, Chandler DC, Kakulas BA, Laing NG. Identification of a point mutation and germinal mosaicism in a Duchenne muscular dystrophy family. Hum Mutat 1994; 3: 133-140
51. Popplewell LJ, Trollet C, Dickson G, Graham IR. Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther 2009; 17: 554-561
52. Wee KB, Pramono ZA, Wang JL, MacDorman KF, Lai PS, Yee WC. Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides. PLoS One 2008; 3: e1844.
53. Silva AL, Romao L. The mammalian nonsense-mediated mRNA decay pathway: To decay or not to decay! Which players make the decision? FEBS Lett 2009; 583: 499-505.
54. Muntoni F, Mateddu A, Marchei F, Clerk A, Serra G. Muscular weakness in the mdx mouse. J Neurol Sci 1993; 120: 71-77
55. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991; 352: 536-539
56. Doran P, Martin G, Dowling P, Jockusch H, Ohlendieck K. Proteome analysis of the dystrophin-deficient mdx diaphragm reveals a drastic increase in the heat shock protein CVHSP. Proteomics 2006; 6: 4610-4621
57. Doran P, Wilton SD, Fletcher S, Ohlendieck K. Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm. Proteomics 2009; 9: 671-685
58. Laws N, Hoey A. Progression of kyphosis in mdx mice. J Appl Physiol 2004; 97: 1970-1977
59. Laws N, Cornford-Nairn RA, Irwin N, Johnsen R, Fletcher S, Wilton SD, et al. Long-term administration of antisense oligonucleotides into the paraspinal muscles of mdx mice reduces kyphosis. J Appl Physiol 2008; 105: 662-668
60. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003; 9: 1009-1014
61. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005; 102: 198-203.
62. Kim Y, Tewari M, Pajerowski JD, Cai S, Sen S, Williams J, et al. Polymersome delivery of siRNA and antisense oligonucleotides. J Control Release 2009; 134: 132-140
63. Sirsi SR, Schray RC, Guan X, Lykens NM, Williams JH, Erney ML, et al. Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice. Hum Gene Ther 2008; 19: 795-806.
64. Sirsi SR, Schray RC, Wheatley MA, Lutz GJ. Formulation of polylactide-co-glycolic acid nanospheres for encapsulation and sustained release of poly(ethylene imine)-poly(ethylene glycol) copolymers complexed to oligonucleotides. J Nanobiotechnol 2009; 7: 1.
65. Williams JH, Sirsi SR, Latta DR, Lutz GJ. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEi copolymers. Mol Ther 2006; 14: 88-96.
66. Rimessi P, Sabatelli P, Fabris M, Braghetta P, Bassi E, Spitali P, et al. Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse. Mol Ther 2009; 17: 820-827
67. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 2006; 8: 207-216
68. Malerba A, Thorogood FC, Dickson G, Graham IR. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 2009; 20: 955-965
69. Vitiello L, Bassi N, Campagnolo P, Zaccariotto E, Occhi G, Malerba A, et al. In vivo delivery of naked antisense oligos in aged mdx mice: Analysis of dystrophin restoration in skeletal and cardiac muscle. Neuromuscul Disord 2008; 18: 597-605.
70. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12: 175-177
71. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, et al. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007; 15: 1587-1592
72. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S, et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008; 16: 1624-1629
73. Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL, et al. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 2009; 18(22): 4405-4414
74. Morcos PA, Li Y, Jiang S. Vivo-morpholinos: A non-peptide transporter delivers morpholinos into a wide array of mouse tissues. Biotechniques 2008; 45: 613-4, 616, 618.
75. Wu B, Li Y, Morcos PA, Doran TJ, Lu P, Lu QL. Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 2009; 17: 864-871
76. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997; 90: 717-727
77. Goyenvalle A, Babbs A, Powell D, Kole R, Fletcher S, Wilton SD, et al. Prevention of dystrophic pathology in severely affected dystrophin/utrophin- deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 2009; 18(1): 198-205.
78. Wang Z, Chamberlain JS, Tapscott SJ, Storb R. Gene therapy in large animal models of muscular dystrophy. ILAR J 2009; 50: 187-198
79. Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S, et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of DUCHENNE muscular dystrophy. Genomics 1992; 13: 115-121
80. Ambrosio CE, Valadares MC, Zucconi E, Cabral R, Pearson PL, Gaiad TP, et al. Ringo, a golden retriever muscular dystrophy (GRMD) dog with absent dystrophin but normal strength. Neuromuscul Disord 2008; 18: 892-893
81. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, et al. Efficacy of systemic morpholino exon-skipping in DUCHENNE dystrophy dogs. Ann Neurol 2009; 65: 667-676
82. t Hoen PA, de Meijer EJ, Boer JM, Vossen RH, Turk R, Maatman RG, et al. Generation and characterization of transgenic mice with the full-length human DMD gene. J Biol Chem 2008; 283: 5899-5907
83. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, et al. In vivo comparison of 2′-o-methyl phosphorothioate and morpholino antisense oligonucleotides for DUCHENNE muscular dystrophy exon skipping. J Gene Med 2009; 11: 257-266
84. Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M, et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 2007; 18: 798-810.
85. Mitrpant C, Adams AM, Meloni PL, Muntoni F, Fletcher S, Wilton SD. Rational design of antisense oligomers to induce dystrophin exon skipping. Mol Ther 2009; 17: 1418-1426
86. Pramono ZA, Takeshima Y, Alimsardjono H, Ishii A, Takeda S, Matsuo M. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 1996; 226: 445-449
87. Takeshima Y, Wada H, Yagi M, Ishikawa Y, Ishikawa Y, Minami R, et al. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev 2001; 23: 788-790
88. Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M, et al. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 2006; 59: 690-694
89. Gebski BL, Errington SJ, Johnsen RD, Fletcher S, Wilton SD. Terminal antisense oligonucleotide modifications can enhance induced exon skipping. Neuromuscul Disord 2005; 15: 622-629
90. Takagi M, Yagi M, Ishibashi K, Takeshima Y, Surono A, Matsuo M, et al. Design of 2′-O-Me RNA/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA. Nucleic Acids Symp Ser (Oxf) 2004: 297-298
91. Yagi M, Takeshima Y, Surono A, Takagi M, Koizumi M, Matsuo M. Chimeric RNA and 2′-O, 4′-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotides in induction of exon 19 skipping in dystrophin mRNA. Oligonucleotides 2004; 14: 33-40.
92. Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, et al. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther 2004; 11: 1391-1398
93. Kole R, Williams T, Cohen L. Rna modulation, repair and remodeling by splice switching oligonucleotides. Acta Biochim Pol 2004; 51: 373-378
94. Yin H, Lu Q, Wood M. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 2008; 16: 38-45.
95. Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJ, Lebleu B, et al. Improved cell-penetrating peptide-PNA conjugates for splicing redirection in hela cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 2008; 36: 6418-6428
96. Gebski BL, Mann CJ, Fletcher S, Wilton SD. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 2003; 12: 1801-1811
97. Wilton SD, Fletcher S. Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: where are we now? Neuromuscul Disord 2005; 15: 399-402.
98. Ruszczak C, Mirza A, Menhart N. Differential stabilities of alternative exon-skipped rod motifs of dystrophin. Biochim Biophys Acta 2009; 1794: 921-928
99. Jorgensen LH, Larochelle N, Orlopp K, Dunant P, Dudley RW, Stucka R, et al. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of Duchenne muscular dystrophy. Hum Gene Ther 2009; 20: 641-650
100. Beroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 2007; 28: 196-202.
101. Fall AM, Johnsen R, Honeyman K, Iversen P, Fletcher S, Wilton SD. Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet Vaccines Ther 2006; 4: 3.
102. Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 2006; 14: 401-407
103. van Vliet L, de Winter CL, van Deutekom JC, van Ommen GJ, Aartsma-Rus A. Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet 2008; 9: 105.
104. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009; 30: 293-299
105. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide pro051. N Engl J Med 2007; 357: 2677-2686
106. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8(10): 918-928
107. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004; 306: 1796-1799
108. Goyenvalle A, Babbs A, van Ommen GJ, Garcia L, Davies KE. Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy. Mol Ther 2009; 17: 1234-1240
109. Chaouch S, Mouly V, Goyenvalle A, Vulin A, Mamchaoui K, Negroni E, et al. Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: Validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cells. Hum Gene Ther 2009; 20(7): 784-790
110. Meregalli M, Farini A, Torrente Y. Combining stem cells and exon skipping strategy to treat muscular dystrophy. Expert Opin Biol Ther 2008; 8: 1051-1061
111. Madden HR, Fletcher S, Davis MR, Wilton SD. Characterisation of a complex DMD-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping. Hum Mutat 2009; 30: 22-28
112. Schwartz M, Duno M, Palle AL, Krag T, Vissing J. Deletion of exon 16 of the dystrophin gene is not associated with disease. Hum Mutat 2007; 28: 205.
113. Tuffery-Giraud S, Beroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: A model of nationwide knowledgebase. Hum Mutat 2009; 30: 934-945
114. Nelson SF, Crosbie RH, Miceli MC, Spencer MJ. Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol 2009; 22: 532-538
115. Kamishikiryo J, Maenaka K. HLA-G molecule. Curr Pharm Des 2009; 15(28): 3318-3324
116. Outeiro TF, Ferreira J. Current and future therapeutic strategies for Parkinson's disease. Curr Pharm Des 2009; 15(34): 3968-3976
117. Rovere-Querini P, Brunelli S, Clementi E, Manfredi AA. Cell death: tipping the balance of autoimmunity and tissue repair. Curr Pharm Des 2008; 14(3): 269-277